Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt No Debt
STXS's Cash-to-Debt is ranked higher than
94% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.55 vs. STXS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
STXS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09  Med: 0.82 Max: No Debt
Current: No Debt
Equity-to-Asset -1.20
STXS's Equity-to-Asset is ranked lower than
98% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. STXS: -1.20 )
Ranked among companies with meaningful Equity-to-Asset only.
STXS' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.33  Med: -0.14 Max: 0.82
Current: -1.2
-1.33
0.82
Piotroski F-Score: 4
Altman Z-Score: -38.12
Beneish M-Score: -2.93
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -18.14
STXS's Operating Margin % is ranked lower than
76% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.15 vs. STXS: -18.14 )
Ranked among companies with meaningful Operating Margin % only.
STXS' s Operating Margin % Range Over the Past 10 Years
Min: -125.3  Med: -29.16 Max: -14.36
Current: -18.14
-125.3
-14.36
Net Margin % 1.03
STXS's Net Margin % is ranked lower than
68% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. STXS: 1.03 )
Ranked among companies with meaningful Net Margin % only.
STXS' s Net Margin % Range Over the Past 10 Years
Min: -180.79  Med: -45.31 Max: 1.03
Current: 1.03
-180.79
1.03
ROA % 1.70
STXS's ROA % is ranked lower than
72% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. STXS: 1.70 )
Ranked among companies with meaningful ROA % only.
STXS' s ROA % Range Over the Past 10 Years
Min: -217.44  Med: -40.99 Max: 1.7
Current: 1.7
-217.44
1.7
ROC (Joel Greenblatt) % 140.49
STXS's ROC (Joel Greenblatt) % is ranked lower than
68% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.96 vs. STXS: 140.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
STXS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3377.46  Med: -420.02 Max: 140.49
Current: 140.49
-3377.46
140.49
3-Year Revenue Growth Rate -23.50
STXS's 3-Year Revenue Growth Rate is ranked lower than
90% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.80 vs. STXS: -23.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
STXS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -15.4 Max: 218.4
Current: -23.5
0
218.4
3-Year EBITDA Growth Rate -72.10
STXS's 3-Year EBITDA Growth Rate is ranked lower than
98% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. STXS: -72.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
STXS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -77.2  Med: -39.4 Max: 19.6
Current: -72.1
-77.2
19.6
3-Year EPS without NRI Growth Rate -55.10
STXS's 3-Year EPS without NRI Growth Rate is ranked lower than
93% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. STXS: -55.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
STXS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -64.6  Med: -35.9 Max: 17.2
Current: -55.1
-64.6
17.2
GuruFocus has detected 3 Warning Signs with Stereotaxis Inc $STXS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» STXS's 30-Y Financials

Financials (Next Earnings Date: 2017-11-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

STXS Guru Trades in Q4 2015

Jim Simons 177,000 sh (+2.49%)
» More
Q1 2016

STXS Guru Trades in Q1 2016

Jim Simons 190,100 sh (+7.40%)
» More
Q2 2016

STXS Guru Trades in Q2 2016

Jim Simons 248,700 sh (New)
Jim Simons Sold Out
» More
Q3 2016

STXS Guru Trades in Q3 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with STXS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 334510    SIC: 3845
Compare:AMEX:RVP, WAR:MMD, AMEX:DXR, OTCPK:NEPH, OTCPK:REPR, NAS:DXTR, NAS:VLRX, NAS:BMRA, NAS:CASM, NAS:SKLN, LSE:AKR, OTCPK:UEEC, OTCPK:ECIA, OTCPK:PEYE, NAS:SSKN, NAS:PDEX, NAS:NURO, AMEX:ISR, NAS:ATEC, OTCPK:RSCF » details
Traded in other countries:RJR1.Germany,
Headquarter Location:USA
Stereotaxis Inc designs, manufactures and markets robotic systems and instruments for use primarily by electrophysiologists for the treatment of abnormal heart rhythms known as cardiac arrhythmias.

Stereotaxis designs a magnetic instrument control system for use in catheter-based cardiology and vascular procedures. The firm markets the Niobe base unit with a user interface system called Navigant and a catheter advancement system named Cardiodrive. In addition, the firm sells software, multiple types of disposable catheters, and an integrated information system called Odyssey. As of December 2010, the firm has installed 164 systems.

Ratios

vs
industry
vs
history
PS Ratio 0.53
STXS's PS Ratio is ranked higher than
94% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.24 vs. STXS: 0.53 )
Ranked among companies with meaningful PS Ratio only.
STXS' s PS Ratio Range Over the Past 10 Years
Min: 0.14  Med: 1.34 Max: 26.83
Current: 0.53
0.14
26.83
EV-to-EBIT 9.65
STXS's EV-to-EBIT is ranked lower than
99.99% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.41 vs. STXS: 9.65 )
Ranked among companies with meaningful EV-to-EBIT only.
STXS' s EV-to-EBIT Range Over the Past 10 Years
Min: -108  Med: -6.75 Max: 32.6
Current: 9.65
-108
32.6
EV-to-EBITDA 6.30
STXS's EV-to-EBITDA is ranked higher than
61% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.62 vs. STXS: 6.30 )
Ranked among companies with meaningful EV-to-EBITDA only.
STXS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -275  Med: -5.9 Max: 426.8
Current: 6.3
-275
426.8
EV-to-Revenue 0.38
STXS's EV-to-Revenue is ranked higher than
98% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.43 vs. STXS: 0.38 )
Ranked among companies with meaningful EV-to-Revenue only.
STXS' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.1  Med: 2 Max: 24.7
Current: 0.38
0.1
24.7
Current Ratio 0.52
STXS's Current Ratio is ranked lower than
97% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.69 vs. STXS: 0.52 )
Ranked among companies with meaningful Current Ratio only.
STXS' s Current Ratio Range Over the Past 10 Years
Min: 0.48  Med: 1.07 Max: 5.72
Current: 0.52
0.48
5.72
Quick Ratio 0.35
STXS's Quick Ratio is ranked lower than
97% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. STXS: 0.35 )
Ranked among companies with meaningful Quick Ratio only.
STXS' s Quick Ratio Range Over the Past 10 Years
Min: 0.35  Med: 0.86 Max: 5.39
Current: 0.35
0.35
5.39
Days Inventory 253.29
STXS's Days Inventory is ranked lower than
89% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 127.43 vs. STXS: 253.29 )
Ranked among companies with meaningful Days Inventory only.
STXS' s Days Inventory Range Over the Past 10 Years
Min: 115.43  Med: 178.88 Max: 253.29
Current: 253.29
115.43
253.29
Days Sales Outstanding 57.26
STXS's Days Sales Outstanding is ranked lower than
54% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.12 vs. STXS: 57.26 )
Ranked among companies with meaningful Days Sales Outstanding only.
STXS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.95  Med: 83.83 Max: 127.77
Current: 57.26
52.95
127.77
Days Payable 82.21
STXS's Days Payable is ranked higher than
85% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.69 vs. STXS: 82.21 )
Ranked among companies with meaningful Days Payable only.
STXS' s Days Payable Range Over the Past 10 Years
Min: 64.34  Med: 116.98 Max: 206.27
Current: 82.21
64.34
206.27

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.50
STXS's 3-Year Average Share Buyback Ratio is ranked lower than
55% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.00 vs. STXS: -4.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
STXS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -289.3  Med: -16.9 Max: -4.5
Current: -4.5
-289.3
-4.5

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.40
STXS's Price-to-Median-PS-Value is ranked higher than
93% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. STXS: 0.40 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
STXS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.14  Med: 2.24 Max: 27.08
Current: 0.4
0.14
27.08
Earnings Yield (Greenblatt) % 10.36
STXS's Earnings Yield (Greenblatt) % is ranked lower than
68% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.70 vs. STXS: 10.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
STXS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -306.9  Med: -12.6 Max: 22.9
Current: 10.36
-306.9
22.9

More Statistics

Revenue (TTM) (Mil) $31.09
EPS (TTM) $ -0.33
Beta2.10
Short Percentage of Float1.34%
52-Week Range $0.47 - 0.91
Shares Outstanding (Mil)22.75
» More Articles for STXS

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: NBN, EMMS, STXS, FOE, NVTL May 21 2012 
Stereotaxis Inc. (STXS) CEO Michael P Kaminski buys 2,800 Shares Jan 04 2011 
Stereotaxis Inc. Reports Operating Results (10-Q) Nov 05 2010 
Stereotaxis Inc. (STXS) CEO Michael P Kaminski buys 2,500 Shares May 11 2010 
Stereotaxis Inc. (STXS) CFO Daniel J Johnston buys 10,000 Shares May 10 2010 
Stereotaxis Inc. Reports Operating Results (10-Q) May 07 2010 
Stereotaxis Inc. Reports Operating Results (10-Q) Nov 06 2009 
Stereotaxis Inc. (STXS) CEO Michael P Kaminski buys 1,410 Shares Sep 03 2009 
Stereotaxis Inc. Reports Operating Results (10-Q) Aug 07 2009 
Stereotaxis Inc. (STXS) CEO Michael P Kaminski buys 2,300 Shares Jun 04 2009 

More From Other Websites
Stereotaxis to Attend Asia Pacific Heart Rhythm Society Conference and Announces Japan Procedure... Sep 11 2017
One Hundred Thousand Procedure Milestone Achieved by Stereotaxis’ Robotic Technology Aug 28 2017
Edited Transcript of STXS earnings conference call or presentation 10-Aug-17 2:00pm GMT Aug 16 2017
Research Finds that Stereotaxis Robotic Technology Provides Significant Advantages in Treatment of... Aug 14 2017
Stereotaxis Reports Second Quarter 2017 Financial Results Aug 10 2017
Investor Network: Stereotaxis, Inc. to Host Earnings Call Aug 10 2017
Stereotaxis to Report Second Quarter 2017 Financial Results on August 10, 2017 Aug 03 2017
Princess Grace Hospital Publishes Data Demonstrating More Rapid Transmural Lesion Formation... Jul 25 2017
Stereotaxis Receives Second Odyssey Vision™ System Orders from Two Leading Heart Hospitals Jul 11 2017
Edited Transcript of STXS earnings conference call or presentation 8-May-17 2:00pm GMT Jun 06 2017
Stereotaxis, Inc. :STXS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017 May 26 2017
Stereotaxis, Inc. :STXS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 23, 2017 Mar 23 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}